Despite Q2/2025 revenue and EPS misses, Organogenesis shares have shown resilience, rarely dipping below $3.00 since June. The company cut 2025 guidance for Advanced Wound Care products, citing ...
Organogenesis has experienced a ~50% share price decline since December 2025, presenting a potential value opportunity. Despite the sharp drop, I remain emboldened by ORGO's high-tech skin substitute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results